Carcinoembryonic antigens (CEA), cancer antigen 125 (CA-125), and prostate-specific antigen (PSA) are quantitatively assessed for the detection and screening of colorectal [6], ovarian [7], and prostate tumors [8], respectively. This evidence concerns the gene MUC16 and prostate neoplasm.